Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17958047 | 1.00 | HCRTR2 (0.41) | HCRTR2NOTUMSRD5A2CTNNB1WNT3A | |
| SCHEMBL29501141 | 0.89 | PHGDH (0.41) | HCRTR2NOTUMCTNNB1WNT3AMEN1 | |
| SCHEMBL17957484 | 0.89 | HDAC8 (0.43) | HCRTR2NOTUMMEN1KMT2A | |
| SCHEMBL17957483 | 0.89 | HDAC8 (0.43) | HCRTR2NOTUMMEN1KMT2A | |
| SCHEMBL17991562 | 0.89 | PHGDH (0.41) | HCRTR2NOTUMCTNNB1WNT3AMEN1 | |
| SCHEMBL17957952 | 0.86 | RARA (0.42) | HCRTR2SRD5A2MEN1KMT2AALDH1A1 | |
| SCHEMBL17957956 | 0.86 | RARA (0.42) | HCRTR2SRD5A2MEN1KMT2AALDH1A1 | |
| SCHEMBL17957748 | 0.78 | RARA (0.40) | HCRTR2CTNNB1WNT3ANPC1ALDH1A1 | |
| SCHEMBL17957750 | 0.78 | RARA (0.40) | HCRTR2CTNNB1WNT3ANPC1ALDH1A1 | |
| SCHEMBL17958062 | 0.78 | HDAC6 (0.44) | HCRTR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009539-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2021-01-14 | — | — | US | disclosed |
| US-10829462-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200055830-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2020-02-20 | — | — | US | disclosed |
| US-10450283-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-10428031-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10421731-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10414738-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190112283-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112281-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190112282-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | Valo Health, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190112280-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20190112279-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2019-04-18 | — | — | US | disclosed |
| WO-2016126722-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160221972-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414738-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-20190112282-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-20190112283-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-20160221972-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-20190112279-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-20190112281-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-20190112280-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-10450283-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-20200055830-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-10428031-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-20210009539-A1 | 3-ALKYL BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-10829462-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
| US-10421731-B2 | 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | HDAC1, HDAC4, HDAC2 | HCRTR2 880/4885NOTUM 4174/4885SRD5A2 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.